You are here

Article Text

Article menu

Download PDFPDF

Poster Presentation
Targeting YAP-dependent MDSC infiltration impairs tumor progression
  1. Guocan Wang1,
  2. Xin Lu1,
  3. Prasenjit Dey1,
  4. Pingna Deng2,
  5. Chia Chin Wu1,
  6. Shan Jiang1,
  7. Zhuangna Fang1,
  8. Kun Zhao1,
  9. Ramakrishna Konaparthi1,
  10. Sujun Hua1,
  11. Jianhua Zhang1,
  12. Elsa M Li Ning Tapia1,
  13. Avnish Kapoor1,
  14. Neelay Patel1,
  15. Zhenglin Guo1,
  16. Vandhana Ramamoorthy1,
  17. Trang Tieu1,
  18. Tim Heffernan1,
  19. Di Zhao1,
  20. Xiaoying Shang1,
  21. Sunada Khadka1,
  22. Pingping Hou1,
  23. Baoli Hu1,
  24. Qing Chang1,
  25. Patricia Troncoso1,
  26. Christopher Logothetis1,
  27. Mark McArthur1,
  28. Lynda Chin3,
  29. Y Alan Wang1 and
  30. Ronald DePinho1
  1. Aff1 grid.240145.60000000122914776The University of Texas MD Anderson Cancer Center Houston TX USA
  2. Aff2 grid.240145.60000000122914776Md anderson cancer center Houston TX USA
  3. Aff3 grid.240145.60000000122914776UT MD Anderson Cancer Center Houston TX USA

http://dx.doi.org/10.1186/2051-1426-3-S2-P421

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Meeting abstracts

    Background

    Myeloid-derived suppressor cells (MDSCs) represent a phenotypically heterogeneous population of immature myeloid cells that play a tumor-promoting role by maintaining a state of immunological anergy and tolerance. Similar to other solid tumor types, Prostate cancer (PCa) is characterized by a rich tumor-stroma interaction network that forms the TME. MDSC abundance in the blood correlates with circulating Prostate Specific Antigen (PSA) levels in PCa patients. MDSCs have been identified recently as a TME constituent in an indolent PCa mouse model with conditional Pten deletion, which antagonized senescence during early tumorigenesis. However, the molecular signaling mechanisms and their cellular origins underlying the recruitment of MDSCs are not well understood and the extent to which MDSCs facilitate PCa progression has not been determined.

    Results

    The signaling mechanisms between cancer cells and infiltrating immune cells of prostate cancer may illuminate novel therapeutic approaches. Here, utilizing a murine prostate adenocarcinoma model driven by loss of Pten and Smad4 (Pb-Cre; PtenL/L;Smad4 L/L), we identify polymorphonuclear myeloid-derived suppressor cells (MDSCs) as the major infiltrating immune cell type and depletion of MDSCs blocks progression. Employing a dual cancer cell and host cell reporter prostate cancer model system (Pb-Cre; PtenL/L;Smad4 L/L;Rosa26-mTmGL/+), transcriptomic profiling of epithelial and stromal constituents identified Cxcl5 as a cancer-secreted chemokine to attract Cxcr2-expressing MDSCs and, correspondingly, pharmacological inhibition of Cxcr2 impeded tumor progression. Integrated analyses identified hyperactivated Hippo-YAP signaling in driving Cxcl5 upregulation in cancer cells through YAP-TEAD complex and promoting MDSCs recruitment. Clinico-pathological studies reveal upregulation and activation of YAP1 in a subset of human prostate tumors, and the YAP1 signature is enriched in these primary prostate tumor samples with stronger expression of MDSC relevant genes. Together, YAP-driven MDSC recruitment via heterotypic Cxcl5-Cxcr2 signaling, which promotes prostate tumor progression, reveals effective anti-MDSC therapeutic interventions for advanced prostate cancer.

    Significance

    This study employs a novel autochthonous prostate cancer model to demonstrate a critical role of MDSCs in tumor progression. In addition, we discover a cancer cell non-autonomous function of Hippo-YAP pathway in regulation of Cxcl5, a ligand for Cxcr2 expressing MDSCs. Pharmacologic elimination of MDSCs or blocking the heterotypic CxCl5-Cxcr2 signaling circuit elicits robust anti-tumor responses in vivo and prolongs survival.